logo
Share SHARE
FONT-SIZE Plus   Neg

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Spanish fashion retailer Industria de Diseño Textil SA or Inditex reported Wednesday higher profit in its first half with strong like-for-like sales growth growth. EBITDA, a key earnings metric, improved 9 percent, while gross margin declined. Inditex shares were losing around 3 percent in the morning trading. Microsoft (MSFT) announced Wednesday that Xbox One X standard edition is now available to pre-order worldwide. The company said more than 130 games have now been enhanced for the system. Beginning today, the console, said to be the most powerful ever, can be booked from local retailers around the... German industrial conglomerate thyssenKrupp AG announced Wednesday that it has signed a memorandum of understanding or MoU with Tata Steel Ltd. about the combination of their European steel activities in a 50/50 joint venture. The companies expect up to 4000 job cuts in the joint venture.
comments powered by Disqus
Follow RTT